- Free from Publisher EAM Gale, SD Beattie, J Hu, V Koivisto, MH … - Diabetes Care, 2007 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Eligible trials were selected from the global
program of an insulin manufacturer. Included were studies in which patients were
seen on a single screening visit, pharmaceutical therapy was not altered ... Cited by 5 - Related articles - BL Direct - All 8 versions
- ►easd.org [PDF] EAM Gale - Diabetologia, 2009 - Springer Drugs for health generate wealth, and wealth drives the diabetes roadshow.
Without it, the subsidised seasonal migrations to our big meetings would grind
to a halt, and the KOLs (Key Opinion Leaders, for the uninitiated) would ... Related articles - All 3 versions
CC Quinn, AL Gruber-Baldini, M Shardell, K … - Contemporary Clinical Trials, 2009 - Elsevier Physician practices (n = 36) in 4 geographic areas are randomly assigned to 1 of
4 study groups. The intervention is a diabetes communication system, using
mobile phones and patient/physician portals to allow patient-specific ... Related articles - All 18 versions
- ►nih.gov SGHA Swinnen, JH DeVries - Diabetologia, 2009 - Springer Abstract Aims/hypothesis The aim of the present study was to investigate whether
predetermined contact frequency with the study team and endpoint insulin dose
are associated with study outcomes in basal insulin initiation trials in ... Related articles - All 3 versions
NR Tripathy, S Basha, R Jain, S Shetty, A … - J Assoc Phys India, 2008 - japi.org INTRODUCTION Exenatide is a 39 – amino acid peptide approved for adjunctive
treatment of type 2 diabetes. It is an incretin mimetic agent that is consistent
in activity with the actions of glucagon–like peptide 1. Proposed ... Cited by 1 - Related articles - View as HTML - All 4 versions
LA Kosmiski, RH Eckel - Clinical Research in Diabetes and Obesity: Diabetes …, 1997 - books.google.com Dyslipidemia in Noninsulin-Dependent Diabetes Mellitus Lisa A. Kosmiski and
Robert H. Eckel Introduction Noninsulin dependent diabetes mellitus (NIDDM) is a
common metabolic dis- order familiar to most physicians. Its complications ... Cited by 2 - Related articles
[CITATION] Inhaled Technosphere Insulin: glucose elimination at the right time?[abstract 443-P]
JL Leahy - The American journal of the medical sciences, 2006 - journals.lww.com ABSTRACT: The majority of patients with type 2 diabe- tes mellitus (T2DM)
eventually require the addition of basal insulin to existing oral therapy to
achieve the glycemic goals set forth by the American Diabetes As- sociation ... Cited by 2 - Related articles - BL Direct - All 6 versions
- Free from Publisher J Rosenstock, R Bergenstal, RA DeFronzo, IB … - Diabetes care, 2008 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Patients (n = 126) were randomly assigned to 12
weeks of therapy with Technosphere insulin or Technosphere powder after
lifestyle education on nutrition, exercise, and instructions on inhaler ... Cited by 2 - Related articles - All 5 versions
MR Lankisch, KC Ferlinz, JL Leahy, WA … - Diabetes, obesity & metabolism, 2008 - ncbi.nlm.nih.gov AIM: To investigate whether the addition of a single bolus of insulin glulisine
(glulisine), administered at either breakfast or main mealtime, in combination
with basal insulin glargine (glargine) and oral antidiabetic drugs (OADs), ... Cited by 2 - Related articles
